Why WHO says Ozempic-like weight-loss drugs shouldn’t be just for the rich – Firstpost

The World Well being Organisation (WHO) has thrown its assist behind a brand new class of weight-loss medicines, recommending the usage of GLP-1 medicines—which mimic a hormone that regulates blood sugar, urge for food, and digestion—as a part of a broader technique to combat rising weight problems charges worldwide.

However the company warned that except pharmaceutical firms reduce costs and scale up manufacturing, lower-income nations might be left behind.

In new therapy tips revealed this week, the WHO issued a “conditional advice” for GLP-1 medicines—together with Wegovy,
Ozempic and Mounjaro—for use alongside more healthy diets, bodily exercise and medical supervision. The advice, the company famous, is conditional as a result of restricted long-term knowledge on security and effectiveness. Most significantly, pregnant girls are excluded from the steerage.

These medication are in all places in richer nations, however the WHO says entry continues to be nowhere close to international.

Additionally learn |
‘Fountain of Youth’: Can Ozempic, the weight-loss drug, assist sluggish ageing?

In response to the company, GLP-1s could attain fewer than 10 p.c of those that may gain advantage by 2030, regardless that a few of the world’s highest weight problems charges are present in Center Japanese, Latin American and Pacific Island nations. As of early this yr, Wegovy was accessible in solely about 15 nations.

The WHO urged drugmakers to undertake tiered pricing fashions for lower-income areas and take into account voluntary licensing to permit different producers to supply GLP-1 medicines. The purpose, officers mentioned, is to stop a widening hole in entry.

“We’d like business to step up,” Jeremy Farrar, WHO assistant director-general, advised Politico. The brand new tips, he mentioned, ship “an amber and inexperienced gentle” for generic producers to arrange cheaper variations as soon as patents start to run out.

Francesca Celletti, a senior weight problems adviser on the WHO, mentioned increasing entry requires “decisive motion,” pointing to how prices of HIV antiretroviral medication collapsed after widespread generic manufacturing. “All of us thought it was not possible… after which the value went down,” she advised Politico.

Key patents on semaglutide—the lively ingredient in Ozempic and Wegovy—will expire in a number of main markets subsequent yr, together with India, Brazil and China, opening the door for generic competitors.

Indian generics chief Dr Reddy’s is already getting ready to launch a semaglutide-based weight-loss drug in 87 nations by 2026, its CEO Erez Israeli mentioned earlier this yr, in line with Reuters. “The US and Europe will open later… and all the opposite Western markets might be open between 2029 and 2033,” Israeli advised reporters after a July earnings launch.

Even with generics, worth is just one impediment.

Many GLP-1 medication require refrigeration and cold-chain logistics, and well being programs should be able to administer them at scale, Celletti famous. “Affordability alone gained’t resolve every little thing,” she mentioned. “Nations want the infrastructure to ship these therapies successfully.”